ClinicalTrials.gg
TerminatedNCT03566823CARMEN CD 306Updated May 11, 2021Results posted

Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)

A Phase 3 interventional study of Ontamalimab and Placebo in Crohn's Disease, sponsored by Shire. Terminated at 145 sites in 20 countries. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-05-11.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
16 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies in Crohn Disease by Takeda — 12 open to participants now, 14 under way, 7 of them phase 3. Crohn Disease · Takeda.

Enrollment
40th of 51
34 · median 100
Started
2018
with 8 others
Phase 3
25 of 86
6 open now
Registered
37th of 86
by date

Among the 86 studies in Crohn Disease by Takeda, this one is the 40th largest by enrollment of the 51 interventional ones that give a count, is one of 9 that started in 2018, is one of 25 in phase 3, and was the 37th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

12 of the 86 studies in Crohn Disease by Takeda are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 16 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Crohn Disease by Takeda, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Ontamalimab in inducing clinical remission and endoscopic response in participants with moderate to severe Crohn's Disease.

Read the detailed description

27Mar2020: Enrollment of new patients into this study has been paused due to the COVID-19 situation. The duration of this pause is dependent on the leveling and control of the COVID-19 pandemic .

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
16 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be between greater than or equal to (> =) 16 and less than or equal to (\<=) 80 years of age; participants less than (\<) 18 years of age must weigh >=40 kg and must have >=16.5 kilogram per meter square (kg/m\^2)
  • Participants must have active moderate to severe ileal (terminal ileum), ileocolic, or colonic CD at baseline (Visit 2) as defined by:

    1. CDAI score between 220 and 450 (inclusive) AND
    2. Meeting the following subscores in the 2 item PRO:

    i. Abdominal pain subscore >= 5 (average worst daily pain on the 11 point NRS) and abdominal pain subscore >= 2 (average daily pain on the 4-point abdominal pain variable of CDAI) over the 7 most recent days out of the 10 days before colonoscopy preparation (may or may not be contiguous) AND/OR ii. Average of the daily stool frequency subscore >=4 of type 6/7 (very soft stools/liquid stools) as shown in the BSFS over the 7 most recent days out of the 10 days before colonoscopy preparation (may or may not be contiguous) c. Presence of ulcerations that are characteristic to CD, as determined by a colonoscopy performed during screening, and as defined by the SES-CD >6 (SES CD >=4 for isolated ileitis) Note that the participant must be confirmed as meeting the CDAI score and PRO subscore requirements before a colonoscopy is done

  • Participants must have a documented diagnosis (endoscopic with histology) of CD for >=3 months before screening. Documented diagnosis is defined as:

    1. A report in which the description of the histological findings is consistent with the CD diagnosis AND
    2. A report documenting disease duration based upon prior colonoscopy Note: If a biopsy report is not available in the source document at the time of screening, a biopsy must be performed during the screening colonoscopy and the histology report should be consistent with the CD diagnosis. If the histology description does not support the CD diagnosis at this time point, the participant should not be randomized
  • Participants must be willing and able to undergo a colonoscopy during screening after all other inclusion criteria have been met
  • Participants must have had an inadequate response to, or lost response to, or had an intolerance to at least 1 conventional treatment such as sulfasalazine or mesalamine (5-aminosalicylic acid [5-ASA]), , or (azathioprine [AZA], 6-mercaptopurine [6-MP] or methotrexate [MTX]) or anti-tumor necrosis factor (anti-TNF). Participants who have had an inadequate response to sulfasalazine or mesalamine should have also failed at least 1 other conventional treatment such as glucocorticoids
  • Participants receiving any treatment(s) for CD are eligible provided they have been, and are anticipated to be, on a stable dose for the designated period of time
  • Participants are males or nonpregnant, nonlactating females who, if sexually active, agree to comply with the requirements of the protocol, or females of nonchildbearing potential. Males and females of who are sexually active must agree to use appropriate contraception (ie, highly effective methods for female and medically appropriate methods for male study participants, for the duration of the study

Exclusion criteria

Exclusion criteria:

  • Participants with indeterminate colitis, microscopic colitis, nonsteroidal anti-inflammatory drug-induced colitis, ischemic colitis, infectious colitis, or clinical/histologic findings suggestive of UC
  • Participants with colonic dysplasia or neoplasia. (Participants with prior history of adenomatous polyps will be eligible if the polyps have been completely removed)
  • Participants with past medical history or presence of toxic megacolon
  • Participants with presence of enterovesical (ie, between the bowel and urinary bladder) or enterovaginal fistulae
  • Participants with current symptomatic diverticulitis or diverticulosis
  • Participants with obstructive colonic stricture, or who have a history of bowel surgery within 6 months before screening, or who are likely to require surgery for CD during the treatment period. Participants who have undergone previous colonic resection or ileocolectomy more than 6 months before screening must have at least 25 cm of colon remaining
  • Participants with past medical history of multiple small bowel resections resulting in clinically significant short bowel syndrome
  • Participants requiring total parenteral nutrition
  • Participants with past medical history of bowel surgery resulting in an existing or current stoma. Participants who had a j-pouch are excluded as a j-pouch could result in a stoma
  • Participants have had prior treatment with ontamalimab (formerly PF-00547659; SHP647)
  • Participants with known or suspected intolerance or to the product(s), closely related compounds, or any of the stated ingredients
  • Participants have received any nonbiologic treatment with immunomodulatory properties (other than AZA, 6-MP, or MTX) or continuous antibiotics (>2 weeks) for the treatment of CD within 30 days before baseline (Visit 2)
  • Participants have received anti-TNF treatment within 60 days before baseline (Visit 2)
  • Participants have received any biologic with immunomodulatory properties (other than anti-TNFs) within 90 days before baseline (Visit 2)
  • Participants have ever received anti-integrin/adhesion molecule treatment (eg, natalizumab,vedolizumab, efalizumab, etrolizumab, or any other investigational anti-integrin/adhesion molecule)
  • Participants have received lymphocytes apheresis or selective monocyte granulocytes apheresis within 60 days before baseline (Visit 2)
  • Participants have received enteral nutrition treatment within 30 days before baseline (Visit 2)
  • Participants have received parenteral or rectal or rectal 5-ASA within 14 days before screening colonoscopy
  • Participants have taken >20 milligram per day(mg/day) of prednisone, >9 mg/day of budesonide, or equivalent oral systemic corticosteroid dose within 14 days before baseline (Visit 2) or have taken >=40 mg/day of prednisone or equivalent oral systemic corticosteroid dose within 6 weeks before baseline (Visit 2)
  • Participants have participated in other investigational studies within either 30 days or 5 half-lives of investigational product used in the study (whichever is longer) before screening (Visit 1)
  • Participants have received a live (attenuated) vaccine within 30 days before the baseline visit (Visit 2)
  • Participants with active enteric infections (positive stool culture and sensitivity), Clostridium difficile infection or pseudomembranous colitis (subjects with C. difficile infection at screening may be allowed retest after treatment), evidence of active cytomegalovirus infection or Listeria monocytogenes, known active invasive fungal infections such as histoplasmosis or parasitic infections, clinically significant underlying disease that could predispose the subjects to infections, or a history of serious infection (requiring parenteral antibiotic and/or hospitalization) within 4 weeks before the baseline visit (Visit 2)
  • Participants with abnormal chest x-ray or other imaging findings at screening (Visit 1), such as presence of active tuberculosis (TB), general infections, heart failure, or (A chest x-ray, computed tomography scan, etc, performed up to 12 weeks before study entry [screening, Visit 1] may be used if available; documentation of the official reading must be located and available in the source documentation)
  • Participants with evidence of active or latent infection with Mycobacterium tuberculosis (TB) or participants with this history who have not completed a generally accepted full course of treatment before baseline (Visit 2) are excluded all other participants must have either the Mantoux (purified protein derivative [PPD]) tuberculin skin test or interferon-gamma release assay (IGRA) performed

Participants who have no history of previously diagnosed active or latent TB are excluded if they have a positive Mantoux (PPD) tuberculin skin test (ie >= 5 millimeter [mm] induration) or a positive IGRA (the latter to be tested at the site's local laboratory) during screening or within 12 weeks before screening If the IGRA cannot be performed locally, a central laboratory may be used, with prior agreement from the sponsor:

  1. An IGRA is strongly recommended for participants with a prior Bacillus Calmette-Guérin vaccination but may be used for any participant Documentation of IGRA product used and the test result must be in the participant's source documentation if performed locally Acceptable IGRA products include QuantiFERON-TB Gold Plus In-Tube Test
  2. If the results of the IGRA are indeterminate, the test may be repeated, and if a negative result is obtained, enrollment may proceed In participants with no history of treated active or latent TB, a positive test on repeat will exclude the participantParticipants with a history of active or latent TB infection must follow instructions for "Participants with a prior diagnosis of active or latent TB are excluded unless both of the following criteria are met" in this criterion
  3. Participants with repeat indeterminate IGRA results, with no prior TB history, may be enrolled after consultation with a pulmonary or infectious disease specialist who determines low risk of infection (ie, participant would be acceptable for [eg, anti-TNF] treatment without additional action) This consultation must be included in source documentation Results from a chest x-ray, taken within the 12 weeks before or during screening (Visit 1)must show no abnormalities suggestive of active TB infection as determined by a qualified medical specialist

    • Participants with a pre-existing demyelinating disorder such as multiple sclerosis or new onset seizures, unexplained sensory motor, or cognitive behavioral, neurological deficits, or significant abnormalities noted during screening
    • Participants with any unexplained symptoms suggestive of PML based on the targeted neurological assessment during the screening period
    • Participants with a transplanted organ. Skin grafts to treat pyoderma gangrenosum are allowed
    • Participants with a significant concurrent medical condition at the time of screening (Visit 1) or baseline (Visit 2), including, but not limited to, the following:

a. Any major illness/condition or evidence of an unstable clinical condition (eg, renal, hepatic, hematologic, GI [except disease under study], endocrine, cardiovascular, pulmonary, immunologic [eg, Felty's syndrome], or local active infection/infectious illness) that, in the investigator's judgment will substantially increase the risk to the subject if he or she participates in the study b. Cancer or history of cancer or lymphoproliferative disease within the previous 5 years (other than resected cutaneous basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix that has been treated with no evidence of recurrence) c. Presence of acute coronary syndrome (eg, acute myocardial infarction, unstable angina pectoris) within 24 weeks before screening (Visit 1) d. History of significant cerebrovascular disease within 24 weeks before screening (Visit 1)

  • Participants who have had significant trauma or major surgery within 4 weeks before the screening (Visit 1), or with any major elective surgery scheduled to occur during the study.
  • Participant with evidence of cirrhosis with or without decompensation (ie, esophageal varices, hepatic encephalopathy, portal hypertension, ascites)
  • Participant with primary sclerosing cholangitis
  • Participant with evidence of positive surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) Note: if a subject tests negative for HBsAg, but positive for HBcAb, the subject would be considered eligible if no presence of hepatitis B virus (HBV) DNA is confirmed by HBV DNA polymerase chain reaction (PCR) reflex testing performed in the central laboratory
  • Participant with chronic virus (HCV) (positive HCV antibody [HCVAb] and HCV RNA) Note: Participant who are HCVAb positive without evidence of HCV RNA may be considered eligible (spontaneous viral clearance or previously treated and cured [defined as no evidence of HCV RNA at least 12 weeks prior to baseline])
  • Participant with any of the following abnormalities in hematology and/or serum chemistry profiles during screening (Visit 1) Note: Screening laboratory tests, if the results are considered by the investigator to be transient and inconsistent with the subject's clinical condition, may be repeated once during the screening period for confirmation results must be reviewed for eligibility prior to the screening colonoscopy procedure

    1. (ALT) and aspartate aminotransferase (AST) levels >=3.0 × the (ULN)
    2. Total level >=1.5 × ULN or >2.0 × ULN if the subject has a known documented history of Gilbert's syndrome
    3. level less than or equal to(\<=80) gram per liter(g/L) (8.0 g/deciliter[dL])
    4. count \<=100× 10\^9/L (100,000 cells/mm\^3) or >=1000 × 10\^9/L (1,000,000 cells/mm\^3)*
    5. White blood cell count \<=3.5 × 10\^9/L (3500 cells/mm\^3)
    6. \<2 × 10\^9/L (2000 cells/mm\^3)
    7. Serum creatinine level >1.5 × ULN or estimated \<30 millilter per minute (mL/min)/173 meter square (m\^2) based on the abbreviated Modification of Diet in RenalDisease Study Equation Note: if platelet count is \<150,000 cells/mm3, a further evaluation should be performed to rule out cirrhosis, unless another etiology has already been identified
  • Participant with known (HIV) infection based on documented history with positive serological test, or positive HIV serologic test at screening, tested at the site's local laboratory in accordance with country requirements or tested at the central laboratory Note: A documented negative HIV test within 6 months of screening is acceptable and does not need to be repeated
  • With known human immunodeficiency virus (HIV) infection based on documented history with positive serological test, or positive HIV serologic test at screening, tested at the site's local laboratory in accordance with country requirements or tested at the central laboratory.
  • Participants who have, or who have a history of (within 2 years before screening), serious psychiatric disease, alcohol dependency, or substance/drug abuse or dependency of any kind including abuse of medicinal marijuana (cannabis)

NOTE: The above Inclusion/Exclusion criteria are NOT exhaustive and other Inclusion/ Exclusion criteria as defined in the protocol may apply.

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Ontamalimab 25 mg

    Participants will receive 25 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.

    Biological: Ontamalimab

  • Experimental
    Ontamalimab 75 mg

    Participants will receive 75 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.

    Biological: Ontamalimab

  • Placebo comparator
    Placebo

    Participants will receive placebo matching with ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.

    Other: Placebo

Interventions

  • BiologicalOntamalimab

    Subcutaneous injection of ontamalimab will be administered using a prefilled syringe.

    Also known as: SHP647, PF-00547659

  • OtherPlacebo

    Subcutaneous injection of placebo matched with ontamalimab will be administered using a prefilled syringe.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Clinical Remission Based on 2-item Patient-reported Outcome (PRO) at Week 16

    Clinical remission was defined by 2-item PRO subs-cores of average worst daily abdominal pain less than or equal to (\<=) 3 (based on 11 point numerical rating scale \[NRS\] ranging from 0 \[no pain\] to 10 \[worst imaginable pain\]); and average daily stool frequency \<=2 of type 6/7 (very soft stools/liquid stools) as per the Bristol Stool Form Scale (BSFS) over the 7 most recent days. BSFS ranges from 1 (separate hard lumps, hard to pass), 2 (sausage-shaped, but lumpy), 3 (like a sausage but with cracks on the surface), 4 (like a sausage or snake, smooth and soft), 5 (soft blobs with clear-cut edges), 6 (fluffy pieces with ragged edges, a mushy stool), 7 (watery, no solid pieces, entirely liquid). Participants with missing data at Week 16 or discontinuation before Week 16 were considered failures. Number of participants with clinical remission were reported.

    Time frame: At Week 16

  2. Number of Participants With Endoscopic Response at Week 16

    Endoscopic response was defined as a decrease in Simple Endoscopic Score for Crohn's disease (SES-CD) of at least 25 percent (%) from baseline. The SES-CD considers ileum, right colon, transverse colon, left colon, rectum in terms of: size of ulcers, ulcerated surface, affected surface and presence of narrowing. Each graded from 0-3. Scale ranges from 0-56 with a higher score indicating greater severity of disease. Participants with missing data at Week 16 or who discontinued before Week 16 were considered failures. Number of participants with endoscopic response were reported.

    Time frame: At Week 16

Secondary outcomes

  1. Number of Participants With Clinical Remission Based on Crohn's Disease Activity Index (CDAI) Score at Week 16

    Clinical remission was defined as a CDAI score of \<150. CDAI assesses CD based on clinical signs/symptoms such as number of liquid stools, intensity of abdominal pain, general well-being (subjective), and presence of complications, use of antidiarrheal, presence of abdominal mass, physical examination and hematocrit (objective). CDAI score is equal to sum of weighted scores for subjective and objective items which range from 0-149 points: asymptomatic remission, 150-220 points: mild to moderate active CD, 221-450 points: moderate to severe active CD, \>451 points: severely active to fulminant disease. Higher score indicating more severity. Number of participants with clinical remission as measured by CDAI were reported.

    Time frame: At Week 16

  2. Number of Participants With Enhanced Endoscopic Response at Week 16

    Enhanced endoscopic response was defined as a decrease in SES-CD by matching segments of at least 50% from baseline. The SES-CD considers ileum, right colon, transverse colon, left colon, rectum in terms of: size of ulcers, ulcerated surface, affected surface and presence of narrowing. Each graded from 0-3. Scale ranges from 0-56 with a higher score indicating greater severity of disease. Participants with missing data at Week 16 or who discontinued before Week 16 were considered non-responders. Number of participants with enhanced endoscopic response were reported.

    Time frame: At Week 16

  3. Number of Participants With Clinical Remission Based on 2-item PRO With 4-point Scale for Abdominal Pain at Week 16

    Clinical remission was defined by 2-item PRO subs-cores of average daily abdominal pain \<=1 (based on the 4 point scale, with scores ranging from 0 \[none\] to 3 \[severe\]) over the 7 most recent days and average daily stool frequency \<=3 of type 6/7 (very soft stools/liquid stools) as per the BSFS over the 7 most recent days. BSFS ranges from 1 (separate hard lumps, hard to pass), 2 (sausage-shaped, but lumpy), 3 (like a sausage but with cracks on the surface), 4 (like a sausage or snake, smooth and soft), 5 (soft blobs with clear-cut edges), 6 (fluffy pieces with ragged edges, a mushy stool), 7 (watery, no solid pieces, entirely liquid). Participants with missing data at Week 16 or who discontinued before Week 16 were considered failures. Number of participants with enhanced endoscopic response were reported.

    Time frame: At Week 16

  4. Number of Participants With Clinical Response Based on 2-item PRO With 2 Criteria at Week 16

    Clinical response was measured by 2-item PRO and defined as meeting at least 1 of the following 2 criteria: 1)A decrease of greater than or equal to (\>=) 30% and at least 2 points from baseline in the average daily worst abdominal pain over the 7 most recent days, with the average daily stool frequency of type 6/7 (very soft stools/liquid stools) either a) not worsening from baseline and/or b) average daily stool frequency \<=2 of type 6/7 as per the BSFS over the 7 most recent days; 2)A decrease of \>=30% from baseline in the average daily stool frequency of type 6/7 (very soft stools/liquid stools) as per the BSFS over the 7 most recent days, with the average daily worst abdominal pain either a) not worsening from baseline and/or b) worst daily abdominal pain \<=3 (based on 11-point NRS) over the 7 most recent days. Participants with missing data at Week16 or who discontinued before Week 16 were considered failures. Number of participants with clinical response were reported.

    Time frame: At Week 16

  5. Number of Participants With Clinical Remission Based on 2-Item PRO With Endoscopic Response at Week 16

    Clinical remission was defined by 2-item PRO subs-cores of average worst daily abdominal pain \<=3 (based on 11 point NRS ranging from 0 \[no pain\] to 10 \[worst imaginable pain\]) over the 7 most recent days and average daily stool frequency \<=2 of type 6/7 (very soft stools/liquid stools) as per BSFS ranging from type 1 (separate hard lumps-like stools) to type 7 (entirely liquid stools) over the 7 most recent days. Endoscopic response was defined as a decrease in SES CD of at least 25% from baseline. The SES-CD considers ileum, right colon, transverse colon, left colon, rectum in terms of: size of ulcers, ulcerated surface, affected surface and presence of narrowing. Each graded from 0-3. Scale ranges from 0-56 with a higher score indicating greater severity of disease. Participants with missing data at Week 16 or who discontinued before Week 16 were considered failures. Number of participants with clinical remission and endoscopic response were reported.

    Time frame: At Week 16

  6. Number of Participants With Complete Endoscopic Healing at Week 16

    Clinical remission was defined by 2-item PRO subs-cores of average worst daily abdominal pain \<=3 (based on 11 point NRS ranging from 0 \[no pain\] to 10 \[worst imaginable pain\]) over the 7 most recent days and average daily stool frequency \<=2 of type 6/7 (very soft stools/liquid stools) as per BSFS ranging from type 1 (separate hard lumps-like stools) to type 7 (entirely liquid stools) over the 7 most recent days. Endoscopic response was defined as a decrease in SES CD of at least 25% from baseline. The SES-CD considers ileum, right colon, transverse colon, left colon, rectum in terms of: size of ulcers, ulcerated surface, affected surface and presence of narrowing. Each graded from 0-3. Scale ranges from 0-56 with a higher score indicating greater severity of disease. Participants with missing data at Week 16 or who discontinued before Week 16 were considered failures. Number of participants with complete endoscopic healing were reported.

    Time frame: At Week 16

  7. Number of Participants With Clinical Response as Measured by CDAI-100 at Week 16

    Clinical response was measured by at least a 100-point reduction in the CDAI from baseline (CDAI-100 response). CDAI assesses CD based on clinical signs/symptoms such as number of liquid stools, intensity of abdominal pain, general well-being (subjective), and presence of complications, use of antidiarrheal, presence of abdominal mass, physical examination and hematocrit (objective). CDAI score is equal to sum of weighted scores for subjective and objective items which range from 0-149 points: asymptomatic remission, 150-220 points: mild to moderate active CD, 221-450 points: moderate to severe active CD, \>451 points: severely active to fulminant disease. Higher score indicating more severity.

    Time frame: At Week 16

  8. Number of Participants With Clinical Response as Measured by CDAI-70 at Week 16

    Clinical response was measured by at least a 70-point reduction in the CDAI from baseline (CDAI-70 response). CDAI assesses CD based on clinical signs/symptoms such as number of liquid stools, intensity of abdominal pain, general well-being (subjective), and presence of complications, use of antidiarrheal, presence of abdominal mass, physical examination and hematocrit (objective). CDAI score is equal to sum of weighted scores for subjective and objective items which range from 0-149 points: asymptomatic remission, 150-220 points: mild to moderate active CD, 221-450 points: moderate to severe active CD, \>451 points: severely active to fulminant disease. Higher score indicating more severity.

    Time frame: At Week 16

  9. Number of Participants With Clinical Remission Over Time

    Clinical remission was defined by 2-item PRO subs-cores of average worst daily abdominal pain (based on 11 point NRS ranging from 0 \[no pain\] to 10 \[worst imaginable pain\]); and average daily stool frequency of type 6/7 (very soft stools/liquid stools) as per BSFS over the 7 most recent days. BSFS ranges from 1 (separate hard lumps, hard to pass), 2 (sausage-shaped, but lumpy), 3 (like a sausage but with cracks on the surface), 4 (like a sausage or snake, smooth and soft), 5 (soft blobs with clear-cut edges), 6 (fluffy pieces with ragged edges, a mushy stool), 7 (watery, no solid pieces, entirely liquid).

    Time frame: At Week 16

  10. Change From Baseline in Individual and Total Sign/Symptom Score Based on Participant Daily Electronic Diary (E-diary) Entries

    CD clinical signs and symptoms includes total stool frequency, rectal bleeding frequency, rectal urgency frequency, nausea severity, vomiting frequency, and rectal incontinence frequency.

    Time frame: Baseline and at Week 16

  11. Number of Participants With Endoscopic Healing at Week 16

    Endoscopic healing was measured by SES-CD \<=4 and at least 2-point reduction versus baseline and no sub-score \>1 in any individual variable. The SES-CD considers ileum, right colon, transverse colon, left colon, rectum in terms of: size of ulcers, ulcerated surface, affected surface and presence of narrowing. Each graded from 0-3. Scale ranges from 0-56 with a higher score indicating greater severity of disease.

    Time frame: At Week 16

  12. Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total (Absolute) Score at Weeks 8, 12 and 16

    The IBDQ is a psychometrically validated PRO instrument for measuring the disease-specific health-related quality of life (HRQL) in participants with IBD, including CD. The IBDQ consists of 32 items, which are grouped into 4 domains and scored as: bowel function (10 to 70), systemic symptoms (5 to 35), emotional status (12 to 84), and social function (5 to 35). The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better HRQL. A score of at least 170 corresponds to clinical remission and an increase of at least 16 points is considered to indicate a clinically meaningful improvement.

    Time frame: Baseline, Weeks 8, 12 and 16

  13. Change From Baseline in Short Form-36 Health Survey (SF-36) Scores at Week 16

    The SF-36, version 2 is a generic quality-of-life instrument that has been widely used to assess HRQL of participants. The SF-36 consists of 36 items that are aggregated into 8 multi-item scales (physical functioning, role - physical, bodily pain, general health, vitality, social functioning, role - emotional, and mental health), with scores ranging from 0 to 100. Higher scores indicate better HRQL.

    Time frame: Baseline, Week 16

  14. Number of Participants Based on Incidence of All-cause Hospitalizations

    Incidence of all cause hospitalizations was planned to be assessed.

    Time frame: Baseline up to Week 32

  15. Number of Participants Based on Total Inpatient Days

    Total inpatient days were planned to be assessed.

    Time frame: Baseline up to Week 32

  16. Number of Participants Based on Incidence of CD-related Surgeries and Other Surgical Procedures

    Incidence of CD-related surgeries and other surgical procedures were planned to be recorded.

    Time frame: Baseline up to Week 32

07

Results

Posted May 11, 2021
Limitations and caveats
The study was terminated as the sponsor discontinued the ontamalimab clinical trial program in ulcerative colitis and CD for reasons unrelated to safety.

Participant flow

The study was conducted at 25 sites in the Unites States, Belgium, Bosnia and Herzegovina, Colombia, Hungary, Japan, Mexico, Slovakia, Republic of Korea, Spain and Ukraine between 17 July 2018 (first participant first visit) and 18 August 2020 (last participant last visit).

Participant flow — Overall Study
MilestonePlaceboOntamalimab 25 mgOntamalimab 75 mg
Started61513
Completed41211
Not completed232
Withdrew: Lack of efficacy010
Withdrew: Withdrawal by subject120
Withdrew: Adverse event102

Outcome measures

PrimaryNumber of Participants With Clinical Remission Based on 2-item Patient-reported Outcome (PRO) at Week 16

Clinical remission was defined by 2-item PRO subs-cores of average worst daily abdominal pain less than or equal to (\<=) 3 (based on 11 point numerical rating scale \[NRS\] ranging from 0 \[no pain\] to 10 \[worst imaginable pain\]); and average daily stool frequency \<=2 of type 6/7 (very soft stools/liquid stools) as per the Bristol Stool Form Scale (BSFS) over the 7 most recent days. BSFS ranges from 1 (separate hard lumps, hard to pass), 2 (sausage-shaped, but lumpy), 3 (like a sausage but with cracks on the surface), 4 (like a sausage or snake, smooth and soft), 5 (soft blobs with clear-cut edges), 6 (fluffy pieces with ragged edges, a mushy stool), 7 (watery, no solid pieces, entirely liquid). Participants with missing data at Week 16 or discontinuation before Week 16 were considered failures. Number of participants with clinical remission were reported.

Time frame:
At Week 16
Reported as:
Count of participants · Participants
Number of Participants With Clinical Remission Based on 2-item Patient-reported Outcome (PRO) at Week 16
ParticipantsPlaceboOntamalimab 25 mgOntamalimab 75 mg
Number of Participants With Clinical Remission Based on 2-item Patient-reported Outcome (PRO) at Week 16355
PrimaryNumber of Participants With Endoscopic Response at Week 16

Endoscopic response was defined as a decrease in Simple Endoscopic Score for Crohn's disease (SES-CD) of at least 25 percent (%) from baseline. The SES-CD considers ileum, right colon, transverse colon, left colon, rectum in terms of: size of ulcers, ulcerated surface, affected surface and presence of narrowing. Each graded from 0-3. Scale ranges from 0-56 with a higher score indicating greater severity of disease. Participants with missing data at Week 16 or who discontinued before Week 16 were considered failures. Number of participants with endoscopic response were reported.

Time frame:
At Week 16
Reported as:
Count of participants · Participants
Number of Participants With Endoscopic Response at Week 16
ParticipantsPlaceboOntamalimab 25 mgOntamalimab 75 mg
Number of Participants With Endoscopic Response at Week 1621010
SecondaryNumber of Participants With Clinical Remission Based on Crohn's Disease Activity Index (CDAI) Score at Week 16

Clinical remission was defined as a CDAI score of \<150. CDAI assesses CD based on clinical signs/symptoms such as number of liquid stools, intensity of abdominal pain, general well-being (subjective), and presence of complications, use of antidiarrheal, presence of abdominal mass, physical examination and hematocrit (objective). CDAI score is equal to sum of weighted scores for subjective and objective items which range from 0-149 points: asymptomatic remission, 150-220 points: mild to moderate active CD, 221-450 points: moderate to severe active CD, \>451 points: severely active to fulminant disease. Higher score indicating more severity. Number of participants with clinical remission as measured by CDAI were reported.

Time frame:
At Week 16
Reported as:
Count of participants · Participants
Number of Participants With Clinical Remission Based on Crohn's Disease Activity Index (CDAI) Score at Week 16
ParticipantsPlaceboOntamalimab 25 mgOntamalimab 75 mg
Number of Participants With Clinical Remission Based on Crohn's Disease Activity Index (CDAI) Score at Week 16486
SecondaryNumber of Participants With Enhanced Endoscopic Response at Week 16

Enhanced endoscopic response was defined as a decrease in SES-CD by matching segments of at least 50% from baseline. The SES-CD considers ileum, right colon, transverse colon, left colon, rectum in terms of: size of ulcers, ulcerated surface, affected surface and presence of narrowing. Each graded from 0-3. Scale ranges from 0-56 with a higher score indicating greater severity of disease. Participants with missing data at Week 16 or who discontinued before Week 16 were considered non-responders. Number of participants with enhanced endoscopic response were reported.

Time frame:
At Week 16
Reported as:
Count of participants · Participants
Number of Participants With Enhanced Endoscopic Response at Week 16
ParticipantsPlaceboOntamalimab 25 mgOntamalimab 75 mg
Number of Participants With Enhanced Endoscopic Response at Week 16253
SecondaryNumber of Participants With Clinical Remission Based on 2-item PRO With 4-point Scale for Abdominal Pain at Week 16

Clinical remission was defined by 2-item PRO subs-cores of average daily abdominal pain \<=1 (based on the 4 point scale, with scores ranging from 0 \[none\] to 3 \[severe\]) over the 7 most recent days and average daily stool frequency \<=3 of type 6/7 (very soft stools/liquid stools) as per the BSFS over the 7 most recent days. BSFS ranges from 1 (separate hard lumps, hard to pass), 2 (sausage-shaped, but lumpy), 3 (like a sausage but with cracks on the surface), 4 (like a sausage or snake, smooth and soft), 5 (soft blobs with clear-cut edges), 6 (fluffy pieces with ragged edges, a mushy stool), 7 (watery, no solid pieces, entirely liquid). Participants with missing data at Week 16 or who discontinued before Week 16 were considered failures. Number of participants with enhanced endoscopic response were reported.

Time frame:
At Week 16
Reported as:
Count of participants · Participants
Number of Participants With Clinical Remission Based on 2-item PRO With 4-point Scale for Abdominal Pain at Week 16
ParticipantsPlaceboOntamalimab 25 mgOntamalimab 75 mg
Number of Participants With Clinical Remission Based on 2-item PRO With 4-point Scale for Abdominal Pain at Week 16366
SecondaryNumber of Participants With Clinical Response Based on 2-item PRO With 2 Criteria at Week 16

Clinical response was measured by 2-item PRO and defined as meeting at least 1 of the following 2 criteria: 1)A decrease of greater than or equal to (\>=) 30% and at least 2 points from baseline in the average daily worst abdominal pain over the 7 most recent days, with the average daily stool frequency of type 6/7 (very soft stools/liquid stools) either a) not worsening from baseline and/or b) average daily stool frequency \<=2 of type 6/7 as per the BSFS over the 7 most recent days; 2)A decrease of \>=30% from baseline in the average daily stool frequency of type 6/7 (very soft stools/liquid stools) as per the BSFS over the 7 most recent days, with the average daily worst abdominal pain either a) not worsening from baseline and/or b) worst daily abdominal pain \<=3 (based on 11-point NRS) over the 7 most recent days. Participants with missing data at Week16 or who discontinued before Week 16 were considered failures. Number of participants with clinical response were reported.

Time frame:
At Week 16
Reported as:
Count of participants · Participants
Number of Participants With Clinical Response Based on 2-item PRO With 2 Criteria at Week 16
ParticipantsPlaceboOntamalimab 25 mgOntamalimab 75 mg
Number of Participants With Clinical Response Based on 2-item PRO With 2 Criteria at Week 165118
SecondaryNumber of Participants With Clinical Remission Based on 2-Item PRO With Endoscopic Response at Week 16

Clinical remission was defined by 2-item PRO subs-cores of average worst daily abdominal pain \<=3 (based on 11 point NRS ranging from 0 \[no pain\] to 10 \[worst imaginable pain\]) over the 7 most recent days and average daily stool frequency \<=2 of type 6/7 (very soft stools/liquid stools) as per BSFS ranging from type 1 (separate hard lumps-like stools) to type 7 (entirely liquid stools) over the 7 most recent days. Endoscopic response was defined as a decrease in SES CD of at least 25% from baseline. The SES-CD considers ileum, right colon, transverse colon, left colon, rectum in terms of: size of ulcers, ulcerated surface, affected surface and presence of narrowing. Each graded from 0-3. Scale ranges from 0-56 with a higher score indicating greater severity of disease. Participants with missing data at Week 16 or who discontinued before Week 16 were considered failures. Number of participants with clinical remission and endoscopic response were reported.

Time frame:
At Week 16
Reported as:
Count of participants · Participants
Number of Participants With Clinical Remission Based on 2-Item PRO With Endoscopic Response at Week 16
ParticipantsPlaceboOntamalimab 25 mgOntamalimab 75 mg
Number of Participants With Clinical Remission Based on 2-Item PRO With Endoscopic Response at Week 16145
SecondaryNumber of Participants With Complete Endoscopic Healing at Week 16

Clinical remission was defined by 2-item PRO subs-cores of average worst daily abdominal pain \<=3 (based on 11 point NRS ranging from 0 \[no pain\] to 10 \[worst imaginable pain\]) over the 7 most recent days and average daily stool frequency \<=2 of type 6/7 (very soft stools/liquid stools) as per BSFS ranging from type 1 (separate hard lumps-like stools) to type 7 (entirely liquid stools) over the 7 most recent days. Endoscopic response was defined as a decrease in SES CD of at least 25% from baseline. The SES-CD considers ileum, right colon, transverse colon, left colon, rectum in terms of: size of ulcers, ulcerated surface, affected surface and presence of narrowing. Each graded from 0-3. Scale ranges from 0-56 with a higher score indicating greater severity of disease. Participants with missing data at Week 16 or who discontinued before Week 16 were considered failures. Number of participants with complete endoscopic healing were reported.

Time frame:
At Week 16
Reported as:
Count of participants · Participants
Number of Participants With Complete Endoscopic Healing at Week 16
ParticipantsPlaceboOntamalimab 25 mgOntamalimab 75 mg
Number of Participants With Complete Endoscopic Healing at Week 16132
SecondaryNumber of Participants With Clinical Response as Measured by CDAI-100 at Week 16

Clinical response was measured by at least a 100-point reduction in the CDAI from baseline (CDAI-100 response). CDAI assesses CD based on clinical signs/symptoms such as number of liquid stools, intensity of abdominal pain, general well-being (subjective), and presence of complications, use of antidiarrheal, presence of abdominal mass, physical examination and hematocrit (objective). CDAI score is equal to sum of weighted scores for subjective and objective items which range from 0-149 points: asymptomatic remission, 150-220 points: mild to moderate active CD, 221-450 points: moderate to severe active CD, \>451 points: severely active to fulminant disease. Higher score indicating more severity.

Time frame:
At Week 16

No measurements were reported for this outcome.

SecondaryNumber of Participants With Clinical Response as Measured by CDAI-70 at Week 16

Clinical response was measured by at least a 70-point reduction in the CDAI from baseline (CDAI-70 response). CDAI assesses CD based on clinical signs/symptoms such as number of liquid stools, intensity of abdominal pain, general well-being (subjective), and presence of complications, use of antidiarrheal, presence of abdominal mass, physical examination and hematocrit (objective). CDAI score is equal to sum of weighted scores for subjective and objective items which range from 0-149 points: asymptomatic remission, 150-220 points: mild to moderate active CD, 221-450 points: moderate to severe active CD, \>451 points: severely active to fulminant disease. Higher score indicating more severity.

Time frame:
At Week 16

No measurements were reported for this outcome.

SecondaryNumber of Participants With Clinical Remission Over Time

Clinical remission was defined by 2-item PRO subs-cores of average worst daily abdominal pain (based on 11 point NRS ranging from 0 \[no pain\] to 10 \[worst imaginable pain\]); and average daily stool frequency of type 6/7 (very soft stools/liquid stools) as per BSFS over the 7 most recent days. BSFS ranges from 1 (separate hard lumps, hard to pass), 2 (sausage-shaped, but lumpy), 3 (like a sausage but with cracks on the surface), 4 (like a sausage or snake, smooth and soft), 5 (soft blobs with clear-cut edges), 6 (fluffy pieces with ragged edges, a mushy stool), 7 (watery, no solid pieces, entirely liquid).

Time frame:
At Week 16

No measurements were reported for this outcome.

SecondaryChange From Baseline in Individual and Total Sign/Symptom Score Based on Participant Daily Electronic Diary (E-diary) Entries

CD clinical signs and symptoms includes total stool frequency, rectal bleeding frequency, rectal urgency frequency, nausea severity, vomiting frequency, and rectal incontinence frequency.

Time frame:
Baseline and at Week 16

No measurements were reported for this outcome.

SecondaryNumber of Participants With Endoscopic Healing at Week 16

Endoscopic healing was measured by SES-CD \<=4 and at least 2-point reduction versus baseline and no sub-score \>1 in any individual variable. The SES-CD considers ileum, right colon, transverse colon, left colon, rectum in terms of: size of ulcers, ulcerated surface, affected surface and presence of narrowing. Each graded from 0-3. Scale ranges from 0-56 with a higher score indicating greater severity of disease.

Time frame:
At Week 16

No measurements were reported for this outcome.

SecondaryChange From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total (Absolute) Score at Weeks 8, 12 and 16

The IBDQ is a psychometrically validated PRO instrument for measuring the disease-specific health-related quality of life (HRQL) in participants with IBD, including CD. The IBDQ consists of 32 items, which are grouped into 4 domains and scored as: bowel function (10 to 70), systemic symptoms (5 to 35), emotional status (12 to 84), and social function (5 to 35). The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better HRQL. A score of at least 170 corresponds to clinical remission and an increase of at least 16 points is considered to indicate a clinically meaningful improvement.

Time frame:
Baseline, Weeks 8, 12 and 16

No measurements were reported for this outcome.

SecondaryChange From Baseline in Short Form-36 Health Survey (SF-36) Scores at Week 16

The SF-36, version 2 is a generic quality-of-life instrument that has been widely used to assess HRQL of participants. The SF-36 consists of 36 items that are aggregated into 8 multi-item scales (physical functioning, role - physical, bodily pain, general health, vitality, social functioning, role - emotional, and mental health), with scores ranging from 0 to 100. Higher scores indicate better HRQL.

Time frame:
Baseline, Week 16

No measurements were reported for this outcome.

SecondaryNumber of Participants Based on Incidence of All-cause Hospitalizations

Incidence of all cause hospitalizations was planned to be assessed.

Time frame:
Baseline up to Week 32

No measurements were reported for this outcome.

SecondaryNumber of Participants Based on Total Inpatient Days

Total inpatient days were planned to be assessed.

Time frame:
Baseline up to Week 32

No measurements were reported for this outcome.

SecondaryNumber of Participants Based on Incidence of CD-related Surgeries and Other Surgical Procedures

Incidence of CD-related surgeries and other surgical procedures were planned to be recorded.

Time frame:
Baseline up to Week 32

No measurements were reported for this outcome.

Adverse events

Collected over From screening up to safety follow-up period (Week 32). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/6 (0%)0/6 (0%)6/6 (100%)
Ontamalimab 25 mg0/15 (0%)2/15 (13.3%)6/15 (40%)
Ontamalimab 75 mg0/13 (0%)2/13 (15.4%)5/13 (38.5%)
Most frequent serious events
Most frequent serious events
EventPlaceboOntamalimab 25 mgOntamalimab 75 mg
Crohn's diseaseGastrointestinal disorders0/61/152/13
Abdominal painGastrointestinal disorders0/60/151/13
Intestinal stenosisGastrointestinal disorders0/60/151/13
GastroenteritisInfections and infestations0/61/150/13
Most frequent other events
Showing 10 of 39
Most frequent other events
EventPlaceboOntamalimab 25 mgOntamalimab 75 mg
Crohn's diseaseGastrointestinal disorders2/60/151/13
Abdominal painGastrointestinal disorders1/60/151/13
ConstipationGastrointestinal disorders1/61/150/13
Large intestinal stenosisGastrointestinal disorders1/60/150/13
Injection site bruisingGeneral disorders1/60/150/13
PyrexiaGeneral disorders1/60/150/13
Fungal skin infectionInfections and infestations1/60/150/13
Respiratory tract infection viralInfections and infestations1/60/150/13
TonsillitisInfections and infestations1/60/150/13
UreteritisInfections and infestations1/60/150/13

Baseline characteristics

The safety set consisted of all participants who had received at least 1 dose of investigational product (IP).

Age, Continuous
Age, Continuous(years)PlaceboOntamalimab 25 mgOntamalimab 75 mgTotal
Mean42.4 ± 13.6037.5 ± 10.2039.1 ± 12.7439.0 ± 11.59
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboOntamalimab 25 mgOntamalimab 75 mgTotal
Female28515
Male47819
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboOntamalimab 25 mgOntamalimab 75 mgTotal
Hispanic or Latino2114
Not Hispanic or Latino4141230
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboOntamalimab 25 mgOntamalimab 75 mgTotal
American Indian or Alaska Native0101
Asian0202
Native Hawaiian or Other Pacific Islander0011
Black or African American1012
White3121126
More than one race0000
Unknown or Not Reported2002
08

Study locations

145 sites
  • Arizona Digestive Health Mesa - East
    Mesa, Arizona 85206, United States
  • Elite Clinical Studies - Phoenix - Clinedge - PPDS
    Phoenix, Arizona 85018, United States
  • Advanced Research Center
    Anaheim, California 92805, United States
  • Kindred Medical Institute for Clinical Trials, LLC
    Corona, California 92879, United States
  • Alliance Clinical Research-(Vestavia Hills)
    Poway, California 92064, United States
  • Care Access Research, San Pablo
    San Pablo, California 94806, United States
  • Renaissance Research Medical Group, INC
    Cape Coral, Florida 33991, United States
  • Gastro Florida
    Clearwater, Florida 33756, United States
  • Alliance Medical Research LLC
    Coral Springs, Florida 33071, United States
  • SIH Research
    Kissimmee, Florida 34741, United States
  • Crystal Biomedical Research
    Miami Lakes, Florida 33065, United States
  • Hi Tech and Global Research, LLc
    Miami, Florida 33135, United States
  • Sanchez Clinical Research, Inc
    Miami, Florida 33157, United States
  • Pharma Research International Inc
    Naples, Florida 34110, United States
  • Bayside Clinical Research - New Port Richey
    New Port Richey, Florida 34655, United States
  • Accel Research Sites - St. Petersburg - ERN - PPDS
    Pinellas Park, Florida 33781, United States
  • DBC Research
    Tamarac, Florida 33321, United States
  • Infinite Clinical Trials
    Atlanta, Georgia 30349, United States
  • Atlanta Center For Gastroenterology PC
    Decatur, Georgia 30033, United States
  • Atlanta Gastroenterology Specialists, PC
    Suwanee, Georgia 30024, United States
  • Loretto Hospital
    Chicago, Illinois 60644, United States
  • IL Gastroenterology Group
    Gurnee, Illinois 60031, United States
  • Cotton O'Neil Clinical Research Center
    Topeka, Kansas 66606, United States
  • Gastroenterology Associates of Hazard
    Hazard, Kentucky 41701, United States
  • CroNOLA, LLC.
    Houma, Louisiana 70360, United States
  • DelRicht Clinical Research, LLC - ClinEdge - PPDS
    New Orleans, Louisiana 70115, United States
  • Commonwealth Clinical Studies LLC
    Brockton, Massachusetts 02302, United States
  • Winchester Gastroenterology Associates
    Winchester, Massachusetts 22601, United States
  • UMass Memorial Medical Center
    Worcester, Massachusetts 01655, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Clinical Research Institute of Michigan
    Chesterfield, Michigan 48047, United States
  • National Clinical, LLC
    Hamtramck, Michigan 48212, United States
  • Gastroenterology Associates of Western Michigan, PLC
    Wyoming, Michigan 49519, United States
  • Mayo Clinic Health System - PPDS
    Duluth, Minnesota 55805, United States
  • Minnesota Gastroenterology PA
    Plymouth, Minnesota 55446, United States
  • Washington University in St. Louis
    Saint Louis, Missouri 63110, United States
  • Advanced Biomedical Research of America
    Las Vegas, Nevada 89123, United States
  • Encompass Care
    North Las Vegas, Nevada 89086, United States
  • NYU Langone Long Island Clinical Research Associates
    Great Neck, New York 11021, United States
  • Southtowns Gastroenterology, PLLC
    Orchard Park, New York 14127, United States
  • Penn State Hershey Medical Group
    State College, Pennsylvania 16803, United States
  • Digestive Health Associates of Texas, P.A.dba DHAT Research Institute
    Garland, Texas 75044, United States
  • Precision Research Institute, LLC
    Houston, Texas 77039, United States
  • Biopharma Informatic Inc.
    Houston, Texas 77043, United States
  • Southwest Clinical Trials
    Houston, Texas 77074, United States
  • BI Research Center
    Houston, Texas 77084, United States
  • Southern Star Research Institute LLC
    San Antonio, Texas 78229, United States
  • Mid Atlantic Health Specialists
    Galax, Virginia 24333, United States
  • Fundación Favaloro
    Buenos Aires, C1093AAS, Argentina
  • Hospital Privado Centro Médico de Córdoba
    Córdoba, Argentina
  • UZ Gent
    Gent, Oost-Vlaanderen 9000, Belgium
  • AZ Groeninge
    Kortrijk, West-Vlaanderen 8500, Belgium
  • CHU Mouscron
    Mouscron, 7700, Belgium
  • Clinical Center Banja Luka
    Banja Luka, 78000, Bosnia and Herzegovina
  • Acibadem City Clinic University Multiprofile Hospital for Active Treatment EOOD
    Sofia, Sofia-Grad 1784, Bulgaria
  • Multiprofile Hospital for Active Treatment Eurohospital
    Plovdiv, 4000, Bulgaria
  • Second Multiprofile Hospital for Active Treatment Sofia
    Sofia, 1202, Bulgaria
  • Diagnostic and Consulting Center Aleksandrovska EOOD
    Sofia, 1431, Bulgaria
  • University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD
    Sofia, 1431, Bulgaria
  • University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna - ISUL EAD
    Sofia, 1527, Bulgaria
  • Medical Center Excelsior OOD - PPDS
    Sofia, 1632, Bulgaria
  • Medical Center Convex EOOD
    Sofia, 1680, Bulgaria
  • Diagnostic Consultative Centre Mladost - M OOD
    Varna, 9000, Bulgaria
  • Fundación Valle Del Lili
    Cali, Valle Del Cauca 760026, Colombia
  • IPS Centro Médico Julián Coronel S.A.S. - PPDS
    Cali, Valle Del Cauca 760035, Colombia
  • OÜ LV Venter
    Parnu, 80010, Estonia
  • West Tallinn Central Hospital
    Tallinn, 10617, Estonia
  • Ippokrateio General Hospital of Athens
    Athens, Attiki 11527, Greece
  • University General Hospital of Heraklion
    Heraklion, 71110, Greece
  • Iatriko Palaiou Falirou
    Paliao Faliro, 17562, Greece
  • University General Hospital of Patras
    Patras, 26504, Greece
  • Euromedica - PPDS
    Thessaloniki, 54645, Greece
  • Magyar Honvédség Egészségügyi Központ
    Budapest, 1062, Hungary
  • Pannónia Magánorvosi Centrum Kft
    Budapest, 1135, Hungary
  • ENDOMEDIX Kft.
    Budapest, 1139, Hungary
  • Bekes Megyei Kozponti Korhaz
    Békéscsaba, 5600, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • Mohacsi Korhaz
    Mohacs, 7700, Hungary
  • Tolna Megyei Balassa János Kórház
    Szekszard, 7100, Hungary
  • Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz
    Székesfehérvár, 8000, Hungary
  • St Vincent's University Hospital
    Dublin, 4, Ireland
  • Sapporo Medical University Hospital
    Sapporo, Hokkaidô 060-8543, Japan
  • Medical Corporation Aoyama Clinic
    Kobe-shi, Hyôgo 650-0015, Japan
  • Hyogo College of Medicine
    Nishinomiya-shi, Hyôgo 663-8501, Japan
  • Kunimoto Hospital
    Asahikawa, 070-0061, Japan
  • Kinshukai Infusion Clinic
    Osaka-shi, 530-0011, Japan
  • Chiinkai Dojima General & Gastroenterology Clinic
    Osaka, 530-0003, Japan
  • Yodogawa Christian Hospital
    Osaka, 533-0024, Japan
  • Toho University Sakura Medical Center
    Sakura, 285-8741, Japan
  • Dokkyo Medical University Hospital
    Shimotsuga-gun, 321-0293, Japan
  • Nihonbashi Egawa Clinic
    Tokyo, 103-0028, Japan
  • Ishida Clinic of IBD and Gastroenterology
    Oita-city, Ôita 870-0823, Japan
  • CHA Bundang Medical Center, CHA University
    Seongnam, Gyeonggido 13496, Korea, Republic of
  • The Catholic University of Korea, St. Vincent's Hospital
    Suwon, Gyeonggido 16247, Korea, Republic of
  • Inje University Haeundae Paik Hospital
    Busan, 48108, Korea, Republic of
  • Pusan National University Hospital
    Busan, 49241, Korea, Republic of
  • Kyungpook National University Hospital
    Daegu, 41944, Korea, Republic of
  • Kyungpook National University Chilgok Hospital
    Daegu, 702-210, Korea, Republic of
  • Gachon University Gil Medical Center
    Incheon, 21565, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of

Showing the first 100 of 145 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Aug 2020, 25 months.

Results were first posted in May 2021, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2018
First posted
Jun 25, 2018
StartActual
Jul 17, 2018
Primary completionActual
Aug 18, 2020
CompletionActual
Aug 18, 2020
Results first posted
May 11, 2021
Last update
May 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03566823
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Jun 25, 2018
Start date
Jul 17, 2018
Primary completion
Aug 18, 2020
Completion
Aug 18, 2020
Results posted
May 11, 2021
Last update
May 11, 2021

Study contacts

Study Director
study director · Shire

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ontamalimab

Start the discussion